Combining high dose external beam radiotherapy with a simultaneous integrated boost to the dominant intraprostatic lesion: Analysis of genito-urinary and rectal toxicityToxicity after integrated boost for prostate cancer

Radiotherapy and Oncology

Volumn 119, Issue 3, 2016, Pages 398-404

  Sundahl, Nora ^a   De Meerleer, Gert ^a   Villeirs, Geert ^a   Ost, Piet ^a   De Neve, Wilfried ^a   Lumen, Nicolaas ^a   De Visschere, Pieter ^a   Van Eijkeren, Marc ^a   Fonteyne, Valérie ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Dose escalation; Intraprostatic lesion; Prostate cancer; Toxicity

Indexed keywords

ACUTE TOXICITY; ADULT; AGED; ARTICLE; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; DISEASE SEVERITY; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; HUMAN; INCIDENCE; INTENSITY MODULATED RADIATION THERAPY; MAJOR CLINICAL STUDY; MALE; MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING; NOCTURIA; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; RADIATION DOSE DISTRIBUTION; RADIATION DOSE FRACTIONATION; RECTUM DISEASE; RISK ASSESSMENT; URINE INCONTINENCE; UROGENITAL TRACT DISEASE; ADVERSE EFFECTS; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; ORGANS AT RISK; PROSTATIC NEOPLASMS; RADIATION RESPONSE; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING SYSTEM; RECTUM; UROGENITAL SYSTEM; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; ORGANS AT RISK; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, INTENSITY-MODULATED; RECTUM; UROGENITAL SYSTEM;

EID: 84965043279     PISSN: 01678140     EISSN: 18790887     Source Type: Journal    
DOI: 10.1016/j.radonc.2016.04.031     Document Type: Article

References (41)

1. [1] Viani, G.A., Stefano, E.J., Afonso, S.L., Higher-than-conventional radiation doses in localized prostate cancer treatment: a meta-analysis of randomized, controlled trials. Int Radiat Oncol Biol Phys 74 (2009), 1405–1418.
2. [2] Nazum, A.E., Movsas, B., Horwitz, A.M., Stobbe, C.C., Chapman, J.D., Incorporating clinical measurements of hypoxia into tumor local control modeling of prostate cancer: implications for the α/β ratio. Int J Radiat Oncol Biol Phys 57 (2003), 391–401.
3. [3] Dearnaley, D.P., Khoo, V.S., Norman, A.R., Meyer, L., Nahum, A., Tait, D., et al. Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial. Lancet 353 (1999), 267–272.
4. [4] Moseley, D.J., White, E.A., Wiltshire, K.L., Rosewall, T., Sharpe, M.B., Siewerdsen, J.H., et al. Comparison of localization performance with implanted fiducial markers and cone-beam computed tomography for on-line image-guided radiotherapy of the prostate. Int Radiat Oncol Biol Phys 67 (2007), 942–953.
5. [5] Pucar, D., Hricak, H., Shukla-Dave, A., Kuroiwa, K., Drobnjak, M., Eastham, J., et al. Clinically significant prostate cancer local recurrence after radiation therapy occurs at the site of primary tumor: magnetic resonance imaging and step-section pathology. Int Radiat Oncol Biol Phys 69 (2007), 62–69.
6. [6] Cellini, N., Morganti, A.G., Mattiucci, G.C., Valentini, V., Leone, M., Luzi, S., et al. Analysis of intraprostatic failures in patients treated with hormonal therapy and radiotherapy: implications for conformal therapy planning. Int J Radiat Oncol Biol Phys 53 (2002), 595–599.
7. [7] Zelefsky, M.J., Reuter, V.E., Fuks, Z., Scardino, P., Shippy, A., Influence of local tumor control on distant metastases and cancer related mortality after external beam radiotherapy for prostate cancer. J Urol 179 (2008), 1368–1373.
8. [8] Lips, I.M., van der Heide, U.A., Haustermans, K., van Lin, E.N., Pos, F., Franken, S.P., et al. Single blind randomized phase III trial to investigate the benefit of a focal lesion ablative microboost in prostate cancer (FLAME-trial): study protocol for a randomized controlled trial. Trials, 12, 2011, 255.
9. [9] Riches, S.F., Payne, G.S., Desouza, N.M., Dearnaley, D., Morgan, V.A., Morgan, S.C., et al. Effect on therapeutic ratio of planning a boosted radiotherapy dose to the dominant intraprostatic tumour lesion within the prostate based on multifunctional MR parameters. Br J Radiol, 87, 2014, 20130813.
10. [10] Onal, C., Sonmez, S., Erbay, G., Guler, O.C., Arslan, G., Simultaneous integrated boost to intraprostatic lesions using different energy levels of intensity-modulated radiotherapy and volumetric-arc therapy. Br J Radiol, 87, 2014, 20130617.
11. [11] Kuang, Y., Wu, L., Hirata, E., Miyazaki, K., Sat, M., Kwee, S.A., Volumetric modulated ard therapy planning for primary prostate cancer with selective intraprostatic boost determined by selective 18F-Choline PET/CT. Int J Radiat Oncol Biol Phys 91 (2015), 1017–1025.
12. [12] Miralbell, R., Molla, M., Rouzaud, M., Hidalgo, A., Toscas, J.I., Lozano, J., et al. Hypofractionated boost to the dominant tumor region with intensity modulated stereotactic radiotherapy for prostate cancer: a sequential dose escalation pilot study. Int Radiat Oncol Biol Phys 78 (2010), 50–57.
13. [13] Ippolito, E., Mantini, G., Morganti, A.G., Mazzeo, E., Padula, G.D., Digesu, C., et al. Intensity-modulated radiotherapy with simultaneous integrated boost to dominant intraprostatic lesion: preliminary report on toxicity. Am J Clin Oncol 35 (2012), 158–162.
14. [14] Pinkawa, M., Piroth, M.D., Holy, R., Klotz, J., Djukic, V., Corral, N.E., et al. Dose-escalation using intensity-modulated radiotherapy for prostate cancer – evaluation of quality of life with and without (18)F-choline PET-CT detected simultaneous integrated boost. Radiat Oncol, 7, 2012, 14.
15. [15] Fonteyne, V., Villeirs, G., Speleers, B., De Neve, W., De Wagter, C., Lumen, N., et al. Intensity-modulated radiotherapy as primary therapy for prostate cancer: report on acute toxicity after dose escalation with simultaneous integrated boost to intraprostatic lesion. Int J Radiat Oncol Biol Phys 72 (2008), 799–807.
16. [16] Jager, G.J., Barentsz, J.O., Oosterhof, G.O., Witjes, J.A., Ruijs, S.J., Pelvic adenopathy in prostatic and urinary bladder carcinoma: MR imaging with a three-dimensional TI-weighted magnetization-prepared-rapid gradient-echo sequence. AJR Am J Roentgenol 167 (1996), 1503–1507.
17. [17] Bolla, M., de Reijke, T.M., Van Tienhoven, G., Van den Bergh, A.C., Oddens, J., Poortmans, P.M., et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 360 (2009), 2516–2527.
18. [18] Barentsz, J.O., Richenberg, J., Clements, R., Choyke, P., Verma, S., Villeirs, G., et al. ESUR prostate MR guidelines 2012. Eur Radiol 22 (2012), 746–757.
19. [19] Ost, P., Speleers, B., De Meerleer, G., De Neve, W., Fonteyne, V., Villeirs, G., et al. Volumetric arc therapy and intensity-modulated radiotherapy for primary prostate radiotherapy with simultaneous integrated boost to intraprostatic lesion with 6 and 18 MV: a planning comparison study. Int Radiat Oncol Biol Phys 79 (2011), 920–926.
20. [20] Fonteyne, V., De Neve, W., Villeirs, G., De Wagter, C., De Meerleer, G., Late radiotherapy-induced lower intestinal toxicity (RILIT) of intensity-modulated radiotherapy for prostate cancer: the need for adapting toxicity scales and the appearance of the sigmoid colon as co-responsible organ for lower intestinal toxicity. Radiat Oncol 84 (2007), 156–163.
21. [21] Sherouse, G.W., Thorn, J., Novins, K., Margolise-Malin, L., Mosher, C., A portable 3D radiotherapy treatment design system. Med Phys, 16, 1989, 466.
22. [22] De Meerleer, G.O., Villeirs, G.M., Vakaet, L., Delrue, L.J., De Neve, W.J., The incidence of inclusion of the sigmoid colon and small bowel in the planning target volume in radiotherapy for prostate cancer. Strahlenther Onkol 180 (2004), 573–581.
23. [23] De Meerleer, G., Vakaet, L., De Gersem, W., Villeirs, G., De Neve, W., Direct segment aperture and weight optimization for intensity-modulated radiotherapy of prostate cancer. Strahlenther Onkol 180 (2004), 136–143.
24. [24] Cox, J.D., Stetz, J., Pajak, T.F., Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int Radiat Oncol Biol Phys 31 (1995), 1341–1346.
25. [25] Ost, P., Lumen, N., Goessaert, A.S., Fonteyne, V., De Troyer, B., Jacobs, F., et al. High-dose salvage intensity-modulated radiotherapy with or without androgen deprivation after radical prostatectomy for rising or persisting prostate-specific antigen: 5-year results. Eur Urol 60 (2011), 842–849.
26. [26] Pickett, B., Vigneault, E., Kurhanewicz, J., Verhey, L., Roach, M., Static field intensity modulation to treat a dominant intra-prostatic lesion to 90 Gy compared to seven field 3-dimensional radiotherapy. Int Radiat Oncol Biol Phys 44 (1999), 921–929.
27. [27] Zelefsky, M.J., Pei, X., Chou, J.F., Schechter, M., Kollmeier, M., Cox, B., et al. Dose escalation for prostate cancer radiotherapy: predictors of long-term biochemical tumor control and distant metastases-free survival outcomes. Eur Urol 60 (2011), 1133–1139.
28. [28] Eade, T.N., Hanlon, A.L., Horwitz, E.M., Buyyounouski, M.K., Hanks, G.E., Pollack, A., What dose of external-beam radiation is high enough for prostate cancer?. Int Radiat Oncol Biol Phys 68 (2007), 682–689.
29. [29] Pinkawa, M., Attieh, C., Piroth, M.D., Holy, R., Nussen, S., Klotz, J., et al. Dose-escalation using intensity-modulated radiotherapy for prostate cancer-evaluation of the dose distribution with and without 18F-choline PET-CT detected simultaneous integrated boost. Radiat Oncol 93 (2009), 213–219.
30. [30] Xia, P., Pickett, B., Vigneault, E., Verhey, L.J., Roach, M. 3rd., Forward or inversely planned segmental multileaf collimator IMRT and sequential tomotherapy to treat multiple dominant intraprostatic lesions of prostate cancer to 90 Gy. Int Radiat Oncol Biol Phys 51 (2001), 244–254.
31. [31] Housri, N., Ning, H., Ondos, J., Choyke, P., Camphausen, K., Citrin, D., et al. Parameters favorable to intraprostatic radiation dose escalation in men with localized prostate cancer. Int Radiat Oncol Biol Phys 80 (2011), 614–620.
32. [32] Fellin, F., Azzeroni, R., Maggio, A., Lorentini, S., Cozzarini, C., Di Muzio, N., et al. Helical tomotherapy and intensity modulated proton therapy in the treatment of dominant intraprostatic lesion: a treatment planning comparison. Radiat Oncol 107 (2013), 207–212.
33. [33] Andrzejewski, P., Kuess, P., Knausl, B., Pinker, K., Georg, P., Knoth, J., et al. Feasibility of dominant intraprostatic lesion boosting using advanced photon-, proton- or brachytherapy. Radiother Oncol 117 (2015), 509–514.
34. [34] Abdellatif, A., Craig, J., Jensen, M., Mulligan, M., Mosalaei, H., Bauman, G., et al. Experimental assessments of intrafractional prostate motion on sequential and simultaneous boost to a dominant intraprostatic lesion. Med Phys 39 (2012), 1505–1517.
35. [35] Rudat, V., Nour, A., Hammoud, M., Alaradi, A., Mohammed, A., Image-guided intensity-modulated radiotherapy of prostate cancer: analysis of interfractional errors and acute toxicity. Strahlenther Onkol, 2015, 10.1007/s00066-015-0919.
36. [36] Le Nobin, J., Rosenkrantz, A.B., Villers, A., Orczyk, C., Deng, F.M., Melamed, J., et al. Image Guided Focal Therapy for magnetic resonance imaging visible prostate cancer: defining a 3-dimensional treatment margin based on magnetic resonance imaging histology co-registration analysis. J Urol 194 (2015), 364–370.
37. [37] Garibaldi, E., Delmastro, E., Gabriele, D., Bresciani, S., Russo, F., Di Dia, A., et al. Clinical and technical feasibility of ultra-boost irradiation in dominant intraprostatic lesion by tomotherapy: preliminary experience and revision of literature. Panminerva Med 58 (2016), 16–22.
38. [38] Uzan, J., Nahum, A.E., Syndikus, I., Prostate dose-painting radiotherapy and radiobiological guided optimisation enhances the therapeutic ratio. Clin Oncol 28 (2016), 165–170.
39. [39] Odrazka, K., Dolezel, M., Vanasek, J., Vaculikova, M., Zouhar, M., Sefrova, J., et al. Late toxicity after conformal and intensity-modulated radiation therapy for prostate cancer: impact of previous surgery for benign prostatic hyperplasia. Int J Urol 17 (2010), 784–790.
40. [40] Kalakota, K., Liauw, S.L., Toxicity after external beam radiotherapy for prostate cancer: an analysis of late morbidity in men with diabetes mellitus. Urology 81 (2013), 1196–1201.
41. [41] Herold, D.M., Hanlon, A.L., Hanks, G.E., Diabetes mellitus: a predictor for late radiation morbidity. J Int Radiat Oncol Biol Phys 43 (1999), 475–479.